Matt has more than 20 years of experience in healthcare investing and more than 15 years as an advisor in investment banking, structuring deals for both small and large capitalization companies. From 2012 to 2021, he was a Managing Director at Foresite Capital, a dedicated healthcare venture and growth equity fund. He served many roles during his nine years at Foresite, including opening their NY office, sourcing and helping manage public and private investments, developing and maintaining relationships with Wall Street banking, research and sales and participating in the Investment Committee.
Prior to that, he was a healthcare portfolio manager at Catapult/Millennium Partners focused on U.S. healthcare services, medical technology, life science tools, big pharmaceutical, and specialty pharmaceutical companies. While at Millennium, Matt managed $400-600 million in combined long/short market neutral capital. Prior to joining Millennium, he was co-founder and co-manager of Sapphire Capital, where he focused on medical technology, diagnostics, life science tools suppliers, diagnostic services, and healthcare information technology.
Matt started his career as an investment banking associate focused on mergers and acquisitions, equity and debt financings and spin-offs. He spent 10 years at Smith Barney as a Director in Investment Banking before becoming Managing Director and Head of Healthcare Investment Banking for Needham and Company. While at Needham, he sourced healthcare venture capital opportunities for their venture capital fund, Needham Capital Partners. After that, Matt was an equity analyst at Argus Partners, a $1 billion healthcare fund where he focused on medical technology, life science tools and diagnostics and specialty services (PBMs). Matt graduated from The Wharton School at the University of Pennsylvania with a BS in economics.
What is Matthew Buten's net worth?
The estimated net worth of Matthew Buten is at least $7.38 million as of October 5th, 2023. Mr. Buten owns 189,380 shares of Biohaven stock worth more than $7,380,139 as of April 28th. This net worth estimate does not reflect any other investments that Mr. Buten may own. Additionally, Mr. Buten receives a salary of $1,050,000.00 as CFO at Biohaven. Learn More about Matthew Buten's net worth.
How old is Matthew Buten?
What is Matthew Buten's salary?
As the CFO of Biohaven Ltd., Mr. Buten earns $1,050,000.00 per year. The highest earning executive at Biohaven is Dr. Vladimir Coric M.D., Chairman & CEO, who commands a salary of $1,960,000.00 per year. Learn More on Matthew Buten's salary.
How do I contact Matthew Buten?
Has Matthew Buten been buying or selling shares of Biohaven?
Matthew Buten has not been actively trading shares of Biohaven during the last quarter. Most recently, on Thursday, October 5th, Matthew Buten bought 22,727 shares of Biohaven stock. The stock was acquired at an average cost of $22.00 per share, with a total value of $499,994.00. Following the completion of the transaction, the chief financial officer now directly owns 189,380 shares of the company's stock, valued at $4,166,360. Learn More on Matthew Buten's trading history.
Who are Biohaven's active insiders?
Biohaven's insider roster includes Irina Antonijevic (Director), Gregory Bailey (Director), Robert Berman (Insider), Matthew Buten (CFO), John Childs (Director), George Clark (CAO), Vlad Coric (CEO), Declan Doogan (Director), James Engelhart (CFO), Kimberly Gentile (SVP), Julia Gregory (Director), William Jones, Jr. (Insider), Elyse Stock (Insider), and John Tilton (Insider). Learn More on Biohaven's active insiders.
Are insiders buying or selling shares of Biohaven?
In the last twelve months, Biohaven insiders bought shares 8 times. They purchased a total of 500,415 shares worth more than $14,301,316.23. In the last twelve months, insiders at the sold shares 1 times. They sold a total of 11,000 shares worth more than $459,690.00. The most recent insider tranaction occured on April, 24th when Director Gregory Bailey bought 25,503 shares worth more than $999,207.54. Insiders at Biohaven own 16.0% of the company.
Learn More about insider trades at Biohaven. Information on this page was last updated on 4/24/2024.
